Kiniksa Pharmaceuticals (NASDAQ:KNSA) Issues Earnings Results, Misses Estimates By $0.17 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17), Briefing.com reports. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The business had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the prior year, the business earned ($0.20) earnings per share. The firm’s quarterly revenue was up 67.4% on a year-over-year basis.

Kiniksa Pharmaceuticals Trading Down 0.7 %

Shares of KNSA stock traded down $0.17 during trading hours on Wednesday, reaching $23.09. The company’s stock had a trading volume of 35,575 shares, compared to its average volume of 410,974. The firm’s fifty day simple moving average is $25.64 and its 200 day simple moving average is $22.42. The stock has a market capitalization of $1.65 billion, a P/E ratio of -145.41 and a beta of 0.33. Kiniksa Pharmaceuticals has a one year low of $14.12 and a one year high of $28.15.

Analyst Ratings Changes

KNSA has been the topic of a number of recent analyst reports. Wedbush lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $33.60.

Insider Buying and Selling

In other news, COO Eben Tessari sold 17,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the sale, the chief operating officer now directly owns 109,975 shares in the company, valued at approximately $2,955,028.25. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the transaction, the insider now owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 112,692 shares of company stock valued at $2,950,315 over the last three months. Corporate insiders own 54.57% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.